A method for the extraction of oxaprozin from equine urine and serum and its quantitation by high-performance liquid chromatography-ultraviolet detection is presented. Confirmation of oxaprozin in postadministration extracts was accomplished by gas chromatographic-mass spectrometric analysis of methylated extracts or liquid chromatography with tandem mass spectrometry daughter ion mass spectra of underivatized extracts. Daypro | a formulation of oxaprozin, was administered orally at a dose of 4.8 g to four standardbred mares. Urine and serum samples were collected to 120 h postadministration. Base hydrolysis of equine urine before extraction resulted in an increase in the amount of oxaprozin measured, an indication of conjugation by ester formation. The urinary elimination profiles of each horse were significantly different from each other with more than one peak in oxaprozin concentration before the 29-31-h collection time. After this collection time, the differences between the oxaprozin urinary concentrations of each horse follow each other more closely. The peak average urinary concentrations of oxaprozin were 25.1 and ] 7.0 pg/mL at collection times of 8-10 and 18-22 h, respectively. The latest detection of oxaprozin in urine was at the last collection time of l 19-121 h postadministration at a concenlration close to the detection limit of approximately 0.1 pg/mL. The serum elimination profiles do not vary between horses as much as the urinary elimination profiles. The peak average serum concentration was 49.0 pg/mL at a collection time of 6 h postadministration. The latest detection was at the last collection time of 120 h. Oxaprozin is metabolized in the horse by hydroxylation. Two major urinary metabolites were isolated and identified as hydroxylated oxaprozin. The two urinary metabolites were isolated from equine postadministration urine and analyzed by mass spectrometry and proton nuclear magnetic resonance spectroscopy, which showed that the hydroxylation had occurred at the para positions of the two aromatic rings.
conducted to determine equine urine and serum oxaprozin concentrations following a dose that might be given to a horse before a race in violation of the rules of horse racing. Of primary importance to this study was the determination of the latest detection and concentrations of oxaprozin in equine urine or serum so that guidelines for the racing industry could be established. In addition to the detection of oxaprozin, confirmation of oxaprozin by mass spectrometry is a requirement in the positive identification of administration of the drug to a horse. Information on the metabolism of oxaprozin in the equine, the mass spectra of these metabolites and structural information pertaining to the metabolites adds useful information that might be used by the racing chemist.
The metabolism of oxaprozin in humans (1) and dogs and monkeys (2) has been studied. Glucuronide ester conjugates, as well as metabolism by hydroxylation in one of the aromatic rings and glucuronide conjugation to form several metabolites was observed in these species.
Several pharmacokinetic studies (3-7) on various aspects of oxaprozin have been reported. These studies include a study on oxaprozin plasma protein binding, which was found to be very high (3) ; the effects of renal disease on oxaprozin clearance (4); synovial tissue and fluid concentrations of oxaprozin in rheumatoid arthritis patients undergoing knee joint surgery (5); clinical trials on rheumatoid arthritis patients given a single daily dose of oxaprozin (6) ; and a study showing that the ingestion of food has no effect on the bioavailability of oxaprozin (7).
Introduction

Materials and Methods
Oxaprozin (Daypro) is a nonsteroidal anti-inflammatory drug used for the treatment of arthritis in humans. This study was 
Administration and sampling
Oxaprozin was administered orally to four standardbred mares at 4.8 g. Eighteen blood samples and 19 urine samples were collected at various intervals to 120 h postadministration. Samples were thawed upon arrival at the laboratory, divided into
Urine extraction
Urine samples (1 mL) were spiked with etodolac (50 IJL of a 200 ng/lJL standard to give a concentration of 10 pg/mL). The pH was adjusted to 13 with 100 IJL of 5M sodium hydroxide (1 mL) and allowed to stand for 10 min. The pH of the urine was readjusted to 5 with 6M hydrochloric acid (2 drops) and sodium acetate buffer (pH 5, 1 mL) and extracted with dichloromethane (5 mL). The organic layer was filtered through phase-separating filters and dried under nitrogen. The residue was reconstituted in mobile phase (200 IJL) for analysis by HPLC-ultraviolet detection (UV).
Serum extradion
Serum samples (1 mL) were spiked with internal standard, etodolac (501JL of a 200 ng/pL standard to give 10 pg/mL). The pH was adjusted to 5 with 1M sodium acetate buffer (pH 5, I mL) and then extracted with dichloromethane (5 mL). The organic layer was filtered through phase separating filters and dried under nitrogen. The residue was reconstituted in mobile phase (100 pL) for analysis by HPLC-UV. 
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Method validation
The limit of detection (LED) and limit of quantitation (LOQ) were defined as the concentration of eight replicate spikes close to the instrument detection limit plus three standard deviations of these spikes and 10 standard deviations, respectively. The spike concentration was 0.10 pg/mL. The LeD and LOQ were calculated to be 0.11 IJg/mL and 0.12 ~g/mL, respectively, in urine and 0.11 pg/mL and 0.15 pg/mL, respectively, in serum. The ruggedness of the methods in urine and serum were measured by the analysis of seven replicate spikes at three concentrations (0.8, 1.0, and 1.2 IJg/mL) on three consecutive days. The intraday percent coefficient of variation (%CV) did not exceed 10% for the seven replicate spikes at three concentrations in urine or serum. The urinary interday %CVs were 5.9 (0.8 pg/mL), 2.8 (1.0 ~g/mL), and 3.8 (1.2 ~g/mL). The serum interday %CVs were 5.4 (0.8 lJg/mL), 6.2 (1.0 IJg/mL), and 4.3 (1.2 IJg/mL).
Quality control (QC) spikes were prepared by an individual other than the person preparing the standard curve in duplicate at 0.8 and 1.2 pg/mL. The QC spikes were found to quantitate to within 6% of expected values for both urine and serum.
Methylation procedure
The dried urine or serum extracts were reconstituted in sodium hydroxide (0.2M, 2 mL), and transferred to a 15-mL screw-cap tube. Tetrabutylammonium hydrogen sulfate (0.1M, 50 pL) and iodomethane (0.5M in dichloromethane, 5 mL) was added to the tube and the mixture heated at approximately 65~ for approximately 30 min with occasional shaking of the tube. The tube was cooled to room temperature, and then the dichloromethane layer was filtered through sodium sulfate and dried under nitrogen. The residue was reconstituted in toluene (200 IJL) for analysis by gas chromatography-mass spectrometry (GC-MS).
Metabolite isolation
Postadministration urine was base hydrolyzed by adjusting the pH of the urine to 13 with 5M sodium hydroxide. The urine pH was readjusted to 9-10 with 5M hydrochloric acid and ammonium hydroxide buffer at pH 9.5. The oxaprozin metabolites were extracted on XAD-2 resin, which was washed with water, 2:1 dichloromethane/ethylacetate, and 10% acetic acid, and then eluted with 3:1 hexane/dichloromethane. The crude extract was streaked onto thin-layer Collection chromatography (TLC) plates which were develtime (h) oped with 90:10 dichloromethane/acetic acid. The bands corresponding to the two metabolites gave a blue fluorescence under short wave light and were scraped from the plates and isolated from the silica gel with methanol.
Administration samples
Urine or serum postadministration samples of a single horse was analyzed in a single batch analysis with QC spikes and duplicate standard because of the number of samples and instrument time required for the analysis. The correlation coefficient for each set of analysis was greater than 0.998, and the QC spikes at 1.0 IJg/mL were within 20% of the expected value. Blank matrix and preadministration urine or serum was extracted with each set of analysis to ensure that there was no contamination of the process.
Urine. Duplicate oxaprozin standard curves were prepared in urine at concentrations of 0, 0.1, 0.5, 1, 5, 10, 20, 50, and 100 pg/mL. QC spikes were prepared at 1.0 lJg/mL in duplicate for each set of analyses. The oxaprozin urinary postadministration concentrations of one horse (H5) were measured without base hydrolysis to determine the extent of glucuronide ester conjugation.
Serum. Duplicate oxaprozin serum standard curves were prepared at concentrations of 0, 0.1, 0.5, 1, 5, 10, 20, and 50 lJg/mL. QC spikes were prepared at 1 pg/mL in duplicate for each set of analyses.
Instrumental analysis
HPLC-UE A Hewlett Packard 1050 LC with a UV detector was used for the quantitation of oxaprozin in urine and serum. The column used was a Phenomenex Luna octyl column (150 x 4.6 mm, 5-pro particle size). The mobile phase was 50:50 acetonitrile/1% acetic acid with a flow rate of 1 mL/min. The injection volume was 10 pL, and the wavelength monitored was 285 nm.
GC-MS.
A Hewlett Packard 5890 GC with a Hewlett Packard 5970A mass selective detector was used for the confirmation of oxaprozin in postadministration samples. The column used was a 30-m x 0.25-ram DB-5 with 5-pro film thickness. The temperature program was 80~ for 2 rain, then increased to 290~ at 25~ with a 4-min hold. The injection volume was 3 pL, with an injector temperature of 250~ and a detector temperature of 300~ The mass range scanned was 50 to 550 ainu. 
LC-MS-MS.
A Perkin Elmer Sciex API HI plus MS with a Spectra Physics P200 LC pump and Spectra Physics AS3500 autosampler was used for the confirmation of oxaprozin in postadministration samples. The column used was a Beckman octy1150 x 4.6-mm column with a particle size of 5 pm. The mobile phase used was 80:20 methanol/0.6% acetic acid in 5mM ammonium acetate with a flow rate of I mL/min. The inlet was a heated nebulizer at a temperature of 400~ in the negative ionization mode. The collision gas thickness was approximately 1013 molecules/cm 2.
Daughter ions of 292 were scanned over a mass range of 50 to 300 amu. Proton NMR. Two major equine urinary metabolites were isolated and analyzed by proton NMR spectroscopy on a Brucker ARX 400 spectrometer. The isolated material was dissolved in deuterated methanol (CD3OD). 
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Results and Discussion
The oxaprozin urinary elimination profiles of the four horses and their average are shown in Figure 1 as a semi-log plot of collection time against concentration. The collection times and oxaprozin concentrations are shown in Table I . Each horse showed two peaks in oxaprozin concentration at different collection times. For example, Horse H5 showed peaks in concentration at 8-10 (18.6 pg/mL) and 22-24 h (11.3 pg/mL), whereas Horse I5 peaked in oxaprozin concentration at 4-8 (7.0 pg/mL) and 18-22 h (32.1 pg/mL). Variations in urinary concentrations of oxaprozin are likely due to variations in metabolism of the drug between horses.
The oxaprozin serum elimination profiles of the four horses and their average are shown in Figure  2 as a semi-log plot of collection time against concentration. The collection times and oxaprozin serum concentrations are shown in Table II . The average peak serum concentration was observed at 6 h and a concentration of 49.0 pg/mL. Only Horse I5 had a peak concentration at 24 h, which is a collection time other than 6 h. Unlike the urine elimination profiles, a single peak in concentration was observed in the serum of these horses.
Base hydrolysis of equine postadministration urine showed an increase in oxaprozin concentration, as shown for Horse H5 in Table I . Ester glucuronidation of oxaprozin has been reported in humans (1) and is postulated as occurring in the horse as evidenced by the increase in concentration with base hydrolysis. To obtain the total oxaprozin concentration (free and ester glu-curonide conjugates), base hydrolysis of the urine is recommended before extraction.
Two major equine urinary metabolites were noted by analysis of the urine extracts under shortwave UV light. Analysis of the extracts showed the two metabolites as blue fluorescent spots under shortwave UV light. These two metabolites were isolated and identified by proton NMR, GC-MS (methylated extracts), and LC-MS-MS. Analytical standards of these metabolites were not available to us, so identification and quantitation of these metabolites in postadministration urine or serum were not possible.
Methylated postadministration urine extracts confirmed the presence of oxaprozin and one of its hydroxylated metabolites. The molecular ions of methyl oxaprozin (307) and its metabolite, dimethylated hydroxyoxaprozin (337), were observed with ions corresponding to loss of CO2CH 3 in both compounds to give base peaks 248 (oxaprozin) and 278 (oxaprozin metabolite). Methylation of the hydroxyl group in the metabolite is an indication that it is aromatic and not an aliphatic hydroxylation. Oxaprozin could be contimed in postadministration urine extracts by daughter ion (292) mass spectra with a heated nebulizer inlet in the negative mode producing M-1 ions. Two major compounds were observed as daughters of ion 308, which corresponds to hydroxylated metabolites of oxaprozin.
The oxaprozin metabolites were isolated from base hydrolyzed urine to optimize the amount of the metabolites present if ester glucuronidation occurred. Without analytical standards, the extent of glucuronidation was not measured. The proposed structures of the two metabolites are shown in Figure 3 , and their proton NMR spectra of the aromatic region in Figure 4 . The two metabolites both showed distinct doublets of doublets that are characteristic of para substitution in an aromatic ring. The second aromatic ring produced a more complex multiplet in the aromatic region.
Conclusions
The serum and urine elimination profiles of oxaprozin administered to four standardbred mares were measured. Oxaprozin concentrations were measured to the last collection time of 120 h in urine and serum. Base hydrolysis of postadministration urine resulted in an increase in the concentration of oxaprozin measured, indicating that metabolism to a glucuronide ester conjugate of oxaprozin occurs in the horse. Two major equine urinary metabolites were isolated and analyzed by GC-MS, LC-MS-MS, and proton NMR. These two metabolites were identified by MS as being monohydroxylated analogues of oxaprozin, with the location of the hydroxylation in an aromatic ring attributable to the methylation of the hydroxyl group by iodomethane. Proton NMR of the aromatic regions of these two metabolites indicates that the hydroxylation is para substituted because of the distinct doublet of doublets observed for one of the aromatic rings in both the metabolites.
